MRCHF.US H.U. Group Holdings Inc
- Market cap
- USD 1.35B
- P/E
- 21.9x
- P/B
- 1.65x
- ROE
- 5.1%
- Dividend yield
- 3.14%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is MRCHF.US undervalued?
Graham numberMRCHF.US trades 26.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
H.U. Group Holdings Inc fundamental analysis
No fundamental analysis for H.U. Group Holdings Inc yet.
H.U. Group Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About H.U. Group Holdings Inc
H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally. The Lab Testing and Its Related Services segment provides general testing services to medical institutions that include esoteric testing, such as genetic and oncology testing; diagnostics-related tests for cancer treatment; omics analysis comprising whole genome sequencing (WGS) and proteome analysis; support for clinical trials an…
Full company profileH.U. Group Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
H.U. Group Holdings Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 204B | 195B | 181B | 189B | 223B | 273B | 261B | 237B | 243B | 249B | 251B |
| Gross Profit | 79.7B | 72.5B | 62.0B | 57.6B | 76.2B | 112B | 89.9B | 63.2B | 67.2B | 71.2B | 75.3B |
| Operating Income | 28.1B | 17.6B | 14.6B | 9.94B | 25.4B | 50.5B | 23.4B | -4.04B | 2.64B | 4.81B | 9.00B |
| EBITDA | 40.0B | 2.89B | 21.3B | 17.7B | 33.6B | 56.3B | 43.0B | 13.7B | 23.1B | 26.6B | 29.3B |
| Net Income | 333M | 257M | 6.39B | -516M | 17.5B | 29.6B | 15.7B | -7.55B | 2.76B | 6.87B | 6.66B |
| EPS | 5.84 | 4.50 | 112 | -9.06 | 306 | 519 | 275 | -133 | 49 | 122 | 122 |
| Balance Sheet | |||||||||||
| Total Assets | 214B | 176B | 201B | 219B | 253B | 287B | 298B | 291B | 280B | 269B | 259B |
| Total Liabilities | 65.8B | 62.8B | 88.3B | 116B | 137B | 146B | 148B | 148B | 142B | 131B | 128B |
| Shareholders' Equity | 148B | 113B | 113B | 103B | 115B | 140B | 150B | 143B | 137B | 138B | 131B |
| Cash & Short-term Investments | 36.0B | 21.0B | 34.4B | 37.1B | 43.8B | 46.7B | 44.4B | 39.9B | 41.1B | 48.4B | 44.6B |
| Total Debt | 10.3B | 8.10B | 49.9B | 71.5B | 80.5B | 73.0B | 77.2B | 81.9B | 86.7B | 74.8B | 60.3B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 36.4B | 15.8B | 16.2B | 15.2B | 35.6B | 55.2B | 32.5B | 16.6B | 22.0B | 21.7B | 18.3B |
| Capital Expenditure | 8.15B | 17.3B | 26.7B | 15.6B | 21.2B | 35.1B | 21.7B | 17.6B | 10.3B | 2.37B | 4.39B |
| Free Cash Flow | 28.3B | -1.53B | -10.5B | -336M | 14.4B | 20.1B | 10.8B | -1.01B | 11.7B | 19.3B | 13.9B |
| Ratios | |||||||||||
| ROE | 0.2% | 0.2% | 5.7% | -0.5% | 15.1% | 21.1% | 10.4% | -5.3% | 2.0% | 5.0% | 5.1% |
| ROA | 0.2% | 0.1% | 3.2% | -0.2% | 6.9% | 10.3% | 5.3% | -2.6% | 1.0% | 2.6% | 2.6% |
| Net Profit Margin | 0.2% | 0.1% | 3.5% | -0.3% | 7.8% | 10.8% | 6.0% | -3.2% | 1.1% | 2.8% | 2.7% |
| Debt to Equity | 0.07x | 0.07x | 0.44x | 0.69x | 0.70x | 0.52x | 0.51x | 0.58x | 0.63x | 0.54x | 0.46x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
H.U. Group Holdings Inc dividends
- Dividend yield
- 3.14%
- Forward dividend
- 0.78 USD
- Payout ratio
- 104.6%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 7.18B | 128 | 104.6% |
| 2025 | JPY 7.14B | 126 | 258.7% |
| 2024 | JPY 7.14B | 126 | - |
| 2023 | JPY 7.14B | 125 | 45.5% |
| 2022 | USD 8.91B | 156 | 30.1% |
| 2021 | USD 6.56B | 115 | 37.6% |
| 2020 | USD 7.42B | 130 | - |
| 2019 | USD 7.41B | 130 | 116.1% |
| 2018 | USD 6.95B | 122 | 2,704.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns H.U. Group Holdings Inc
- Insiders 0.02%
- Institutions 56.93%
- Public & others 43.05%
- Shares outstanding 54.1M
- Free float 54.3M
H.U. Group Holdings Inc company profile
- Company name
- H.U. Group Holdings Inc
- Ticker
- MRCHF.US
- ISIN
- JP3822000000
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5,157
- Fiscal year end
- March
- Address
- Akasaka Intercity AIR, Tokyo, Japan, 107-0052
- Phone
- 81 3 6279 0801
- Website
- hugp.com
About H.U. Group Holdings Inc
H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally. The Lab Testing and Its Related Services segment provides general testing services to medical institutions that include esoteric testing, such as genetic and oncology testing; diagnostics-related tests for cancer treatment; omics analysis comprising whole genome sequencing (WGS) and proteome analysis; support for clinical trials and research, including pre-trial setup work, specimen collection and transport, measuring, result reports, and data management, as well as SaaS for general practitioners and personal health records. Its In-Vitro Diagnostics segment provides Lumipulse system products, an automated chemiluminescence enzyme immunoassay system that offers reagents; testing services for neurodegenerative diseases; and diagnostics kit for infectious diseases comprising influenza and COVID-19, as well as cerebrospinal fluid reagent. This segment also develops blood-based reagents and biomarkers specifically for neurodegenerative diseases, such as Alzheimer's. The Healthcare-related Services segment offers in-house sterilization for central supply rooms in hospitals and external sterilization at sterilization centers; operating room support, endoscopy room support, medical equipment maintenance and inspection, and logistics management and transportation services; support for important tasks related to hospital administration work, including the sale of medical equipment, supplies, and consumables related to central supply rooms and operating rooms; and home medical care and nursing services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.
H.U. Group Holdings Inc management
8- Mr. Goki IshikawaPresident, Group CEO, Representative Executive Officer & Director · born 1976
- Hisashi YamakawaManager of IR/SR Department - Corporate Planning Division
- Mr. Katsumi AoyagiExecutive Officer of R&D
- Isao TadaDivision Head of Procurement Division
- Mr. Makoto MatsumotoManaging Executive Officer, LTS · born 1968
- Prof. Takayuki YoshizumiExecutive Officer, Human Resources and General Affairs · born 1969
- Masao HasegawaExecutive Officer
- Mr. Tadashi HasegawaExecutive Officer · born 1970